A phase 2 local clinical study of Solucin® neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET)
Latest Information Update: 04 Sep 2019
At a glance
- Drugs Lu-177 octreotide (Primary)
- Indications Gastro-enteropancreatic neuroendocrine tumour; Pancreatic cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Sep 2019 New trial record
- 02 Sep 2019 According to an ITM Solucin, DuChemBio Co Media release, the companies plan to initiate a local clinical study for ITM's Solucin TRT which is expected to begin recruiting patients in 2020. The concept of this study is based on ITM's Phase III clinical trial COMPETE.